Abstract
Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.
Keywords: Anxiety, anxiolytic-like, cannabis sativa, cannabidiol, CBD, major depression.
CNS & Neurological Disorders - Drug Targets
Title:Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa
Volume: 13 Issue: 6
Author(s): Alexandre R. de Mello Schier, Natalia P. de Oliveira Ribeiro, Danielle S. Coutinho, Sergio Machado, Oscar Arias-Carrion, Jose A. Crippa, Antonio W. Zuardi, Antonio E. Nardi and Adriana C. Silva
Affiliation:
Keywords: Anxiety, anxiolytic-like, cannabis sativa, cannabidiol, CBD, major depression.
Abstract: Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.
Export Options
About this article
Cite this article as:
Schier R. de Mello Alexandre, Ribeiro P. de Oliveira Natalia, Coutinho S. Danielle, Machado Sergio, Arias-Carrion Oscar, Crippa A. Jose, Zuardi W. Antonio, Nardi E. Antonio and Silva C. Adriana, Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa, CNS & Neurological Disorders - Drug Targets 2014; 13 (6) . https://dx.doi.org/10.2174/1871527313666140612114838
DOI https://dx.doi.org/10.2174/1871527313666140612114838 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heterocyclic Secretase Inhibitors for the Treatment of Alzheimer’s Disease: An Overview
Central Nervous System Agents in Medicinal Chemistry The Gene Expression Profiles of Medulloblastoma Cell Lines Resistant to Preactivated Cyclophosphamide
Current Cancer Drug Targets Cover Image Description for CAR 13-4
Current Alzheimer Research MicroRNAs in CAG Trinucleotide Repeat Expansion Disorders: an Integrated Review of the Literature
CNS & Neurological Disorders - Drug Targets Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry Hydrazonoyl Halides as Precursors for Synthesis of Bioactive Thiazole and Thiadiazole Derivatives: Synthesis, Molecular Docking and Pharmacological Study
Current Organic Synthesis Flavonoids and Polyphenolic Compounds as Potential Talented Agents for the Treatment of Alzheimer’s Disease and their Antioxidant Activities
Current Pharmaceutical Design Small Molecule Antagonists of the Chemokine Receptor CCR5
Current Topics in Medicinal Chemistry Studying the Human Gut Microbiota in the Trans-Omics Era - Focus on Metagenomics and Metabonomics
Current Pharmaceutical Design Adsorption of Antifungal Drugs Inside Pristine and Functionalized Fullerenes and Nanotubes: DFT Investigation
Current Computer-Aided Drug Design The role of Nox-mediated oxidation in the regulation of cytoskeletal dynamics
Current Pharmaceutical Design Fetal Asphyctic Preconditioning Protects Against Perinatal Asphyxia- Induced Apoptosis and Astrogliosis in Neonatal Brain
CNS & Neurological Disorders - Drug Targets The Effects of Soluble Aβ Oligomers on Neurodegeneration in Alzheimer's Disease
Current Pharmaceutical Design Blood Coagulation as an Intrinsic Pathway for Proinflammation: A Mini Review
Inflammation & Allergy - Drug Targets (Discontinued) Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence
Current Neuropharmacology The Psychoactive Effects of Aromatic Amino Acids
Current Nutrition & Food Science Editorial (Thematic Selection: Inflammatory and Immune Responses in Depression)
Current Neuropharmacology Survey of Epstein Barr Virus (EBV) Immunogenic Proteins and their Epitopes: Implications for Vaccine Preparation
Recent Patents on Anti-Infective Drug Discovery Formulation and Optimization of Ethosomes for Transdermal Delivery of Ropinirole Hydrochloride
Current Drug Delivery The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory
Current Pharmaceutical Design